Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
purified chicken-embryo cell rabies vaccine
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
Purified chicken-embryo cell rabies vaccine (PCEC or PCECV) is an inactivated viral vaccine developed for the prevention of rabies in humans. The vaccine is produced by propagating an attenuated rabies virus strain (such as Flury LEP or Pitman-Moore) in primary chick embryo cell cultures. After virus propagation, the virus is inactivated using β-propiolactone, concentrated, purified, and lyophilized. It is administered intramuscularly or intradermally for both pre-exposure and post-exposure prophylaxis. The vaccine induces high titers of rabies virus neutralizing antibodies, conferring protective immunity against rabies virus infection. Several brands exist worldwide, using similar production methods but differing in strain and formulation. PCECV is recommended by the World Health Organization as a modern rabies vaccine, with proven safety and efficacy in multiple clinical studies[1][3][4][5][6].
- Brand names
- VaxiRab NRabipurRabAvertChiroRab
- Other names
- purified chick embryo cell vaccinechick embryo cell rabies vaccinePCEC rabies vaccine
02
Targets
RABV-G (Rabies virus glycoprotein)
Beyond the preview
Go deeper on purified chicken-embryo cell rabies vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on purified chicken-embryo cell rabies vaccine.